Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Meir Wetzler

Showing results (1-10 of 120) with videos related to

Pageof 12
Sort By:
Current Pharmaceutical Design|February 8, 2011
Omacetaxine as an anticancer therapeutic: what is old is new againMeir Wetzler, David Segal
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 12, 2011
Therapeutic advances in acute myeloid leukemiaAlan Burnett, Meir Wetzler, Bob Löwenberg
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 12, 2009
Targeting signal transducer and activator of transcription signaling pathway in leukemiasMustafa Benekli, Heinz Baumann, Meir Wetzler
Expert Opinion on Biological Therapy|December 10, 2008
Pegasparaginase: where do we stand?Amer Zeidan, Eunice S Wang, Meir Wetzler
International Immunology|August 11, 2004
Characterization of dendritic-like cells derived from t(9;22) acute lymphoblastic leukemia blastsJaewoo Lee, Sheila N Sait, Meir Wetzler
Leukemia Research|January 15, 2008
Epigenetic regulation of signal transducer and activator of transcription 3 in acute myeloid leukemiaSampa Ghoshal Gupta, Heinz Baumann, Meir Wetzler
Hematology/Oncology Clinics of North America|October 15, 2009
Looking toward the future: novel strategies based on molecular pathogenesis of acute lymphoblastic leukemiaSyed A Abutalib, Meir Wetzler, Wendy Stock
Clinical Advances in Hematology & Oncology : H&O|October 2, 2008
What is imatinib-resistant chronic myeloid leukemia? Identifying and managing loss of responseAmer Zeidan, Eunice S Wang, Meir Wetzler
British Journal of Haematology|October 12, 2013
Genetics on a WHIMOmar Al Ustwani, Razelle Kurzrock, Meir Wetzler
Leukemia Research Reports|December 28, 2013
The use of low-dose protracted oral clofarabine in a patient with myelodysplastic syndrome after failing 5-azacitidineOmar Al Ustwani, Jessica D Greene, Meir Wetzler
Pageof 12

Showing results (1-10 of 120) with videos related to

Sort By:
Pageof 12
Current Pharmaceutical Design|February 8, 2011
Omacetaxine as an anticancer therapeutic: what is old is new againMeir Wetzler, David Segal
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 12, 2011
Therapeutic advances in acute myeloid leukemiaAlan Burnett, Meir Wetzler, Bob Löwenberg
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 12, 2009
Targeting signal transducer and activator of transcription signaling pathway in leukemiasMustafa Benekli, Heinz Baumann, Meir Wetzler
Expert Opinion on Biological Therapy|December 10, 2008
Pegasparaginase: where do we stand?Amer Zeidan, Eunice S Wang, Meir Wetzler
International Immunology|August 11, 2004
Characterization of dendritic-like cells derived from t(9;22) acute lymphoblastic leukemia blastsJaewoo Lee, Sheila N Sait, Meir Wetzler
Leukemia Research|January 15, 2008
Epigenetic regulation of signal transducer and activator of transcription 3 in acute myeloid leukemiaSampa Ghoshal Gupta, Heinz Baumann, Meir Wetzler
Hematology/Oncology Clinics of North America|October 15, 2009
Looking toward the future: novel strategies based on molecular pathogenesis of acute lymphoblastic leukemiaSyed A Abutalib, Meir Wetzler, Wendy Stock
Clinical Advances in Hematology & Oncology : H&O|October 2, 2008
What is imatinib-resistant chronic myeloid leukemia? Identifying and managing loss of responseAmer Zeidan, Eunice S Wang, Meir Wetzler
British Journal of Haematology|October 12, 2013
Genetics on a WHIMOmar Al Ustwani, Razelle Kurzrock, Meir Wetzler
Leukemia Research Reports|December 28, 2013
The use of low-dose protracted oral clofarabine in a patient with myelodysplastic syndrome after failing 5-azacitidineOmar Al Ustwani, Jessica D Greene, Meir Wetzler
Pageof 12